Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 5/20 | 0.46 |
| ▸ | MMP9 | P14780 | 5/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650893 | 0.94 | MAPT (0.53) | PTPN1MAPTMEN1KMT2AACHE | |
| SCHEMBL4651215 | 0.87 | PTPN1 (0.60) | PTPN1MEN1KMT2AMMP2MMP9 | |
| SCHEMBL4650968 | 0.84 | PTPN1 (0.62) | PTPN1MMP2MMP9 | |
| SCHEMBL4650871 | 0.82 | PTPN1 (0.62) | PTPN1MMP2MMP9ALDH1A1MAPK1 | |
| SCHEMBL4651310 | 0.82 | PTPN1 (0.57) | PTPN1MMP2MMP9ALDH1A1GAA | |
| SCHEMBL4650268 | 0.82 | PTPN1 (0.58) | PTPN1MEN1KMT2AMMP2MMP9 | |
| SCHEMBL4651374 | 0.79 | PTPN1 (0.56) | PTPN1MAPTALDH1A1MAPK1 | |
| SCHEMBL4651102 | 0.79 | PTPN1 (0.61) | PTPN1MAPTMMP2MMP9ALDH1A1 | |
| SCHEMBL4650251 | 0.78 | PTPN1 (0.62) | PTPN1MAPTALDH1A1 | |
| SCHEMBL4650882 | 0.78 | PTPN1 (0.69) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301474-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | Array Biopharma Inc. (US) | 2003-04-16 | — | — | EP | claimed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | claimed |
| WO-2002004412-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2002-01-17 | — | — | WO | claimed |
| EP-1301474-B1 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-6586467-B2 | Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus | ARRAY BIOPHARMA INC. | 2003-07-01 | — | — | US | disclosed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040003-A1 | Preparation of phosphatase inhibitors | PTPRS, PTPRO, PTPRR | PTPN1 5/4885MAPT 4307/4885MEN1 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.